

DAFTAR PUSTAKA

- Amdur, R. J., & Bankert, E. A. (2010). *Institutional review board member handbook*. Jones & Bartlett Publishers.
- Anderson, K. K., & Mukherjee, S. D. (2007). The need for additional safeguards in the informed consent process in schizophrenia research. *J Med Ethics*, 33(11), 647–650. <https://doi.org/10.1136/jme.2006.017376>
- Appelbaum, P. S. (2019). In search of a new paradigm for research on violence and schizophrenia. *Am J Psychiatry*, 176(9), 677–679. <https://doi.org/10.1176/appi.ajp.2019.19070678>
- Arksey, H., & O'Malley, L. (2005). Scoping studies: towards a methodological framework. *International Journal of Social Research Methodology*, 8(1), 19–32. <https://doi.org/10.1080/1364557032000119616>
- Ashok, A. H., Baugh, J., & Yeragani, V. K. (2012). Paul Eugen Bleuler and the origin of the term schizophrenia. *Indian J Psychiatry*, 54(1), 95–96. <https://doi.org/10.4103/0019-5545.94660>
- Azorin, J.-M., Belzeaux, R., & Adida, M. (2014). Negative symptoms in schizophrenia: where we have been and where we are heading. *CNS Neurosci Ther*, 20(9), 801–808. <https://doi.org/10.1111/cns.12292>
- Barata, R. B. (2008). Ethics in epidemiological research. *Cien Saude Colet*, 13(2), 453–548. <https://doi.org/10.1590/s1413-81232008000200020>
- Beebe, L. H., & Smith, K. (2010). Informed consent to research in persons with schizophrenia spectrum disorders. *Nurs Ethics*, 17(4), 425–434. <https://doi.org/10.1177/0969733010364581>
- Benson, P. R., Roth, L. H., & Winslade, W. J. (1985). Informed consent in psychiatric research: preliminary findings from an ongoing investigation. *Sot. Sci. Med*, 20(12), 1331–1341. [https://doi.org/10.1016/0277-9536\(85\)90388-0](https://doi.org/10.1016/0277-9536(85)90388-0)
- Blanco, C., Compton, W. M., & Weiss, S. R. B. (2017). From epidemiology to interventions and back. *Am J Psychiatry*, 174(10), 915–916. <https://doi.org/10.1176/appi.ajp.2017.17070796>
- Bola, J. R. (2005). Medication-free research in early episode schizophrenia: evidence of long-term harm? *Schizophr Bull*, 32(2), 288–296. <https://doi.org/10.1093/schbul/sbj019>

- Boutros, N. N., Mucci, A., Diwadkar, V., & Tandon, R. (2014). Negative symptoms in schizophrenia. *Clin Schizophr Relat Psychoses*, 8(1), 28-35B. <https://doi.org/10.3371/CSRP.BOMU.012513>
- Brekke, J. S., Prindle, C., Bae, S. W., & Long, J. D. (2001). Risks for individuals with schizophrenia who are living in the community. *Psychiatric Services*, 52(10), 1358-1366. <https://doi.org/10.1176/appi.ps.52.10.1358>
- Brisch, R., Saniotis, A., Wolf, R., Bielau, H., Bernstein, H.-G., Steiner, J., Bogerts, B., Braun, K., Jankowski, Z., & Kumaratilake, J. (2014). The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. *Frontiers in Psychiatry*, 5, 47. <https://doi.org/doi.org/10.3389/fpsyt.2014.00047>
- Brown, A. S. (2010). The environment and susceptibility to schizophrenia. *Prog Neurobiol*, 93(1), 23-58. <https://doi.org/10.1016/j.pneurobio.2010.09.003>
- Candilis, P. J., Fletcher, K. E., Geppert, C. M. A., Lidz, C. W., & Appelbaum, P. S. (2008). A direct comparison of research decision-making capacity: Schizophrenia/schizoaffective, medically ill, and non-ill subjects. *Schizophrenia Research*, 99(1-3), 350-358. <https://doi.org/10.1016/j.schres.2007.11.022>
- Cannon, T. D., Van Erp, T. G. M., Bearden, C. E., Loewy, R., Thompson, P., Toga, A. W., Huttunen, M. O., Keshavan, M. S., Seidman, L. J., & Tsuang, M. T. (2003). Early and late neurodevelopmental influences in the prodrome to schizophrenia: contributions of genes, environment, and their interactions. *Schizophrenia Bulletin*, 29(4), 653-669. <https://doi.org/doi.org/10.1093/oxfordjournals.schbul.a007037>
- Carpenter, W. T., & Conley, R. R. (1999). Sense and nonsense:: an essay on schizophrenia research ethics. *Schizophrenia Research*, 35(3), 219-225. [https://doi.org/https://doi.org/10.1016/s0920-9964\(98\)00128-5](https://doi.org/https://doi.org/10.1016/s0920-9964(98)00128-5)
- Carpenter, W. T., Schooler, N. R., & Kane, J. M. (1997). The rationale and ethics of medication-free research in schizophrenia. *Archives of General Psychiatry*, 54(5), 401-407. <https://doi.org/10.1001/archpsyc.1997.01830170015002>
- Charlson, F. J., Ferrari, A. J., Santomauro, D. F., Diminic, S., Stockings, E., Scott, J. G., McGrath, J. J., & Whiteford, H. A. (2018). Global epidemiology and burden of schizophrenia: Findings from the global burden of disease study 2016. *Schizophr Bull*, 44(6), 1195-1203. <https://doi.org/10.1093/schbul/sby058>

- Chen, D. T., & Moreno, J. D. (2006). Ethics of medication-free research in schizophrenia. *Schizophrenia Bulletin*, 32(2), 307–309. <https://doi.org/10.1093/schbul/sbj049>
- Chiodo, G. T., Tolle, S. W., & Bevan, L. (2000). Placebo-controlled trials: good science or medical neglect? *West J Med*, 172(4), 271–273. <https://doi.org/10.1136/ewjm.172.4.271>
- Clayton, E. W., Evans, B. J., Hazel, J. W., & Rothstein, M. A. (2019). The law of genetic privacy: applications, implications, and limitations. *Journal of Law and the Biosciences*, 6(1), 1–36. <https://doi.org/https://doi.org/10.1093/jlb/lbz007>
- Council for International Organizations of Medical Sciences. (1982). International guidelines for biomedical research with human beings. *Geneva: CIOMS/OMS*.
- Council for International Organizations of Medical Sciences. (2016). *International ethical guidelines for health-related research involving humans*. Council for International Organizations of Medical Sciences.
- Cullen, R., & Marshall, S. (2006). Genetic research and genetic information: a health information professional's perspective on the benefits and risks. *Health Info Libr J*, 23(4), 275–282. <https://doi.org/10.1111/j.1471-1842.2006.00666.x>
- Demasi, M., & Jefferson, T. (2021). Placebo-The unknown variable in a controlled trial. *JAMA Intern Med*, 181(5), 577–578. <https://doi.org/10.1001/jamainternmed.2020.8670>
- Dufva, Y. E., Westman, H., Khilbom, U., Sullivan, P. F., & Johansson, V. (2021). Swedish large-scale schizophrenia study: Why do patients and healthy controls participate? *Schizophrenia Research*, 228, 360–366. <https://doi.org/10.1016/j.schres.2021.01.007>
- Dunn, L. B. (2007). Ethical issues in schizophrenia: considerations for treatment and research. *Psychopharmacol Bull*, 40(4), 145–155.
- Dunn, L. B., Candilis, P. J., & Roberts, L. W. (2005). Emerging empirical evidence on the ethics of schizophrenia research. *Schizophr Bull*, 32(1), 47–68. <https://doi.org/10.1093/schbul/sbj012>
- Dunn, L. B., & Jeste, D. V. (2003). Problem areas in the understanding of informed consent for research: Study of middle-aged and older patients with psychotic disorders. *Psychopharmacology*, 171(1), 81–85. <https://doi.org/10.1007/s00213-003-1501-3>

- Dunn, L. B., Kim, D. S., Fellows, I. E., & Palmer, B. W. (2009). Worth the risk? Relationship of incentives to risk and benefit perceptions and willingness to participate in schizophrenia research. *Schizophrenia Bulletin*, *35*(4), 730–737. <https://doi.org/10.1093/schbul/sbn003>
- Dunn, L. B., Palmer, B. W., Appelbaum, P. S., Saks, E. R., Aarons, G. A., & Jeste, D. V. (2007). Prevalence and correlates of adequate performance on a measure of abilities related to decisional capacity: Differences among three standards for the MacCAT-CR in patients with schizophrenia. *Schizophrenia Research*, *89*(1–3), 110–118. <https://doi.org/10.1016/j.schres.2006.08.005>
- Dunn, L. B., Palmer, B. W., & Keehan, M. (2006). Understanding of placebo controls among older people with schizophrenia. *Schizophrenia Bulletin*, *32*(1), 137–146. <https://doi.org/10.1093/schbul/sbi069>
- Dunn, L. B., Palmer, B. W., Keehan, M., Dilip Jeste, B. V., & Appelbaum, P. S. (2006). Assessment of Therapeutic Misconception in Older Schizophrenia Patients With a Brief Instrument. *Am J Psychiatry*, *163*(3), 500–506. <https://doi.org/10.1176/appi.ajp.163.3.500>
- Dunn, L. B., & Roberts, L. W. (2005). Emerging findings in ethics of schizophrenia research. *Current Opinion in Psychiatry*, *18*(2), 111–119. <https://doi.org/10.1097/00001504-200503000-00003>
- Emsley, R., Chiliza, B., Asmal, L., & Harvey, B. H. (2013). The nature of relapse in schizophrenia. *BMC Psychiatry*, *13*, 1–8. <https://doi.org/10.1186/1471-244X-13-50>
- Fereday, J., & Muir-Cochrane, E. (2006). Demonstrating rigor using thematic analysis: A hybrid approach of inductive and deductive coding and theme development. *International Journal of Qualitative Methods*, *5*(1), 80–92. <https://doi.org/10.1177/160940690600500107>
- Fidalgo, T. M., & Brunoni, A. R. (2019). Epidemiological research in psychiatry: acting globally. *Braz J Psychiatry*, *41*(2), 99–100. <https://doi.org/10.1590/1516-4446-2019-4102>
- Fischer, B. A., & George, P. (2010). The investigator and the IRB: A survey of depression and schizophrenia researchers. *Schizophrenia Research*, *122*(1–3), 206–212. <https://doi.org/10.1016/j.schres.2009.12.019>
- Fischer, B. A., McMahon, R. P., Meyer, W. A., Slack, D. J., Appelbaum, P. S., & Carpenter, W. T. (2013). Participants with schizophrenia retain the information

- necessary for informed consent during clinical trials. *Journal of Clinical Psychiatry*, 74(6), 622–627. <https://doi.org/10.4088/JCP.12m07997>
- Fleischhacker, W. W., Czobor, P., Hummer, M., Kemmler, G., Kohnen, R., & Volavka, J. (2003). Placebo or active control trials of antipsychotic drugs? *Archives of General Psychiatry*, 60(5), 458–464. <https://doi.org/10.1001/archpsyc.60.5.458>
- Foley, C., Corvin, A., & Nakagome, S. (2017). Genetics of schizophrenia: Ready to translate? *Curr Psychiatry Rep*, 19(9), 61. <https://doi.org/10.1007/s11920-017-0807-5>
- Fovet, T., Amad, A., Thomas, P., & Jardri, R. (2014). [Schizophrenia and informed consent to research]. *Encephale*, 41(5), 394–402. <https://doi.org/10.1016/j.encep.2014.07.004>
- Frank, E., Novick, D. M., & Kupfer, D. J. (2003). Beyond the question of placebo controls: ethical issues in psychopharmacological drug studies. *Psychopharmacology*, 171, 19–26. <https://doi.org/10.1007/s00213-003-1477-z>
- Frith, C. D., Blakemore, S.-J., & Wolpert, D. M. (2000). Explaining the symptoms of schizophrenia: abnormalities in the awareness of action. *Brain Research Reviews*, 31(2–3), 357–363. [https://doi.org/10.1016/S0165-0173\(99\)00052-1](https://doi.org/10.1016/S0165-0173(99)00052-1)
- Gebregziabhere, Y., Habatmu, K., Mihretu, A., Cella, M., & Alem, A. (2022). Cognitive impairment in people with schizophrenia: an umbrella review. *Eur Arch Psychiatry Clin Neurosci*, 272(7), 1139–1155. <https://doi.org/10.1007/s00406-022-01416-6>
- Häfner, H., & an der Heiden, W. (1997). Epidemiology of schizophrenia. *The Canadian Journal of Psychiatry*, 42(2), 139–151. <https://doi.org/10.1177/070674379704200204>
- Hjorthøj, C., Stürup, A. E., McGrath, J. J., & Nordentoft, M. (2017). Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. *Lancet Psychiatry*, 4(4), 295–301. [https://doi.org/10.1016/S2215-0366\(17\)30078-0](https://doi.org/10.1016/S2215-0366(17)30078-0)
- Hlaing, W. M., Kushch, N. A., Wells, A. E., & Goodman, K. W. (2021). Common topics discerned in ethics in epidemiology and public health syllabi: in-depth review. *Ann Epidemiol*, 60, 31–34. <https://doi.org/10.1016/j.annepidem.2021.04.014>

- Hoehe, M. R., & Morris-Rosendahl, D. J. (2018). The role of genetics and genomics in clinical psychiatry. *Dialogues Clin Neurosci*, 20(3), 169–177. <https://doi.org/10.31887/DCNS.2018.20.3/mhoehe>
- Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021). A method for tapering antipsychotic treatment that may minimize the risk of relapse. *Schizophrenia Bulletin*, 47(4), 1116–1129. <https://doi.org/10.1093/schbul/sbab017>
- Howes, O. D., & Murray, R. M. (2014). Schizophrenia: an integrated sociodevelopmental-cognitive model. *The Lancet*, 383(9929), 1677–1687. [https://doi.org/10.1016%2FS0140-6736\(13\)62036-X](https://doi.org/10.1016%2FS0140-6736(13)62036-X)
- Hyder, A. A., Dawson, L., Bachani, A. M., & Lavery, J. V. (2009). Moving from research ethics review to research ethics systems in low-income and middle-income countries. *The Lancet*, 373(9666), 862–865. [https://doi.org/10.1016/S0140-6736\(09\)60488-8](https://doi.org/10.1016/S0140-6736(09)60488-8)
- Institute of Health Metrics and Evaluation. (2019). *Global burden of disease 2019*. University of Washington.
- Jauhar, S., Johnstone, M., & McKenna, P. J. (2022). Schizophrenia. *Lancet*, 399(10323), 473–486. [https://doi.org/10.1016/S0140-6736\(21\)01730-X](https://doi.org/10.1016/S0140-6736(21)01730-X)
- Javitt, D. C. (2022). Cognitive impairment associated with schizophrenia: From pathophysiology to Treatment. *Annu Rev Pharmacol Toxicol*, 63, 119–141. <https://doi.org/10.1146/annurev-pharmtox-051921-093250>
- Jayaram, M. B., & Hosalli, P. (2005). Risperidone versus olanzapine for schizophrenia. *Cochrane Database Syst Rev*, 2, CD005237. <https://doi.org/10.1002/14651858.CD005237>
- Jeste, D. V, Palmer, B. W., Appelbaum, P. S., Golshan, S., Glorioso, D., Dunn, L. B., Kim, K., Meeks, T., & Kraemer, H. C. (2007). A new brief instrument for assessing decisional capacity for clinical research. *Arch Gen Psychiatry*, 64(8), 966–974. <https://doi.org/10.1001/archpsyc.64.8.966>
- Joanna Briggs Institute. (2020). *JBİ manual for evidence synthesis*. JBI. <https://doi.org/https://jbi-global-wiki.refined.site/space/MANUAL>
- Kaminsky, A., Roberts, L. W., & Brody, J. L. (2003). Influences upon Willingness to Participate in Schizophrenia Research: An Analysis of Narrative Data from 63 People with Schizophrenia. *Ethics and Behavior*, 13(3), 279–302. https://doi.org/10.1207/S15327019EB1303_06

- Kaup, A. R., Dunn, L. B., Saks, E. R., Jeste, D. v, & Palmer, B. W. (2011). Decisional capacity and consent for schizophrenia research. *IRB*, 33(4), 1–9. <https://www.ncbi.nlm.nih.gov/pubmed/21932481>
- Keefe, R. S. E., & Fenton, W. S. (2007). How should DSM-V criteria for schizophrenia include cognitive impairment? *Schizophrenia Bulletin*, 33(4), 912–920. <https://doi.org/10.1093%2Fschbul%2Fsbm046>
- Kemenkes RI. (2019). *Riset Kesehatan Dasar 2018*. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/http://repository.bkpk.kemkes.go.id/3514/1/Laporan%20Riskasdas%202018%20Nasional.pdf
- Keränen, T., Halkoaho, A., Itkonen, E., & Pietilä, A.-M. (2015). Placebo-controlled clinical trials: how trial documents justify the use of randomisation and placebo. *BMC Med Ethics*, 16, 2. <https://doi.org/10.1186/1472-6939-16-2>
- Kessler, R. C. (2007). Psychiatric epidemiology: challenges and opportunities. *Int Rev Psychiatry*, 19(5), 509–521. <https://doi.org/10.1080/09540260701564914>
- Khan, Z. U., Martin-Montañez, E., & Muly, E. C. (2013). Schizophrenia: causes and treatments. *Curr Pharm Des*, 19(36), 6451–6461. <https://doi.org/10.2174/1381612811319360006>
- Kim, S. Y. H., Appelbaum, P. S., Swan, J., Stroup, T. S., McEvoy, J. P., Goff, D. C., Jeste, D. V., Lambert, J. S., Leibovici, A., & Caine, E. D. (2007). Determining when impairment constitutes incapacity for informed consent in schizophrenia research. *British Journal of Psychiatry*, 191(JULY), 38–43. <https://doi.org/10.1192/bjp.bp.106.033324>
- Knoppers, B. M., & Chadwick, R. (2005). Human genetic research: emerging trends in ethics. *Nat Rev Genet*, 6(1), 75–79. <https://doi.org/10.1038/nrg1505>
- Komite Etik Penelitian dan Pengembangan Kesehatan Nasional Kementerian Kesehatan RI. (2021). *Pedoman dan standar etik penelitian dan pengembangan kesehatan nasional*. Kemenkes RI.
- Koocher, G. P., & Keith-Spiegel, P. (2008). *Ethics in psychology and the mental health professions: Standards and cases*. Oxford University Press.
- Kovnick, J. A., Appelbaum, P. S., Hoge, S. K., & Leadbetter, R. A. (2003). Competence to consent to research among long-stay inpatients with chronic schizophrenia. *Psychiatric Services*, 54(9), 1247–1252. <https://doi.org/10.1176/appi.ps.54.9.1247>

- Kring, A. M., & Elis, O. (2012). Emotion deficits in people with schizophrenia. *Annu Rev Clin Psychol*, 9, 409–433. <https://doi.org/10.1146/annurev-clinpsy-050212-185538>
- Kumra, S., Briguglio, C., Lenane, M., Goldhar, L., Bedwell, J., Venuchekov, J., Jacobsen, L. K., & Rapoport, J. L. (1999). Including Children and Adolescents With Schizophrenia in Medication-Free Research. *Am J Psychiatry*, 156, 7. <https://doi.org/10.1176/ajp.156.7.1065>
- Ladea, M., & Prelipceanu, D. (2009). Markers of vulnerability in schizophrenia. *J Med Life*, 2(2), 155–164. <https://www.ncbi.nlm.nih.gov/pubmed/20108534>
- Lahti, A. C., Warfel, D., Michaelidis, T., Weiler, M. A., Frey, K., & Tamminga, C. A. (2001). Long-Term Outcome of Patients Who Receive Ketamine during Research. *Biol Psychiatry*, 49(10), 869–875. [https://doi.org/10.1016/s0006-3223\(00\)01037-4](https://doi.org/10.1016/s0006-3223(00)01037-4)
- Lenroot, R., Bustillo, J. R., Lauriello, J., & Keith, S. J. (2003). Integrated treatment of schizophrenia. *Psychiatr Serv*, 54(11), 1499–1507. <https://doi.org/10.1176/appi.ps.54.11.1499>
- Lo, L. E., Kaur, R., Meiser, B., & Green, M. J. (2020). Risk of schizophrenia in relatives of individuals affected by schizophrenia: a meta-analysis. *Psychiatry Research*, 286, 112852. <https://doi.org/10.1016/j.psychres.2020.112852>
- López-Jaramillo, C., Tobler, C. A., Gómez, C. O., & Triana, J. E. (2016). Correlation between insight and capacity to consent to research in subjects with bipolar disorder type I and schizophrenia. *Revista Colombiana de Psiquiatria*, 45(3), 194–200. <https://doi.org/10.1016/j.rcp.2016.01.002>
- Mannarini, S., Taccini, F., Sato, I., & Rossi, A. A. (2022). Understanding stigma toward schizophrenia. *Psychiatry Res*, 318, 114970. <https://doi.org/10.1016/j.psychres.2022.114970>
- McCutcheon, R. A., Marques, T. R., & Howes, O. D. (2020). Schizophrenia—an overview. *JAMA Psychiatry*, 77(2), 201–210. <https://doi.org/10.1001/jamapsychiatry.2019.3360>
- McGrath, J. J., & Susser, E. S. (2009). New directions in the epidemiology of schizophrenia. *Med J Aust*, 190(S4), S7–9. <https://doi.org/10.5694/j.1326-5377.2009.tb02366.x>

- Meli, G., Öttl, B., Paladini, A., & Cataldi, L. (2012). Prenatal and perinatal risk factors of schizophrenia. *The Journal of Maternal-Fetal & Neonatal Medicine*, 25(12), 2559–2563. <https://doi.org/doi.org/10.3109/14767058.2012.699118>
- Mihaljević-Peleš, A., Bajš Janović, M., Šagud, M., Živković, M., Janović, Š., & Jevtović, S. (2019). Cognitive deficit in schizophrenia: an overview. *Psychiatr Danub*, 31(Suppl 2), 139–142. <https://www.ncbi.nlm.nih.gov/pubmed/31158113>
- Millum, J., & Grady, C. (2013). The ethics of placebo-controlled trials: methodological justifications. *Contemp Clin Trials*, 36(2), 510–514. <https://doi.org/10.1016/j.cct.2013.09.003>
- Mion, A. B. Z., & Ventura, C. A. A. (2023). The WHO QualityRights Initiative and its use worldwide: A literature review. *International Journal of Social Psychiatry*, 00207640231207580.
- Misra, S. (2012). Randomized double blind placebo control studies, the “Gold Standard” in intervention based studies. *Indian J Sex Transm Dis AIDS*, 33(2), 131–134. <https://doi.org/10.4103/0253-7184.102130>
- Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012). Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. *Molecular Psychiatry*, 17(12), 1206–1227. <https://doi.org/https://doi.org/10.1038/mp.2012.47>
- Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009). Academia and clinic annals of internal medicine preferred reporting items for systematic reviews and meta-analyses. *Annu Intern Med*, 151(4), 264–269. <https://doi.org/10.7326/0003-4819-151-4-200908180-00135>
- Morris, S. E., & Heinssen, R. K. (2014). Informed consent in the psychosis prodrome: ethical, procedural and cultural considerations. *Philos Ethics Humanit Med*, 9, 19. <https://doi.org/10.1186/1747-5341-9-19>
- Moser, D. J., Reese, R. L., Schultz, S. K., Benjamin, M. L., Arndt, S., Fleming, F. W., & Andreasen, N. C. (2005). Informed consent in medication-free schizophrenia research. *Am J Psychiatry*, 162(6), 1209–1211. <https://doi.org/10.1176/appi.ajp.162.6.1209>
- Moustafa, A. A., Garami, J. K., Mahlberg, J., Golembieski, J., Keri, S., Misiak, B., & Frydecka, D. (2016). Cognitive function in schizophrenia: conflicting findings and future directions. *Rev Neurosci*, 27(4), 435–448. <https://doi.org/10.1515/revneuro-2015-0060>

- Müller, D. J. (2020). Pharmacogenetics in Psychiatry. *Pharmacopsychiatry*, 53(4), 153–154. <https://doi.org/10.1055/a-1212-1101>
- National Human Genome Research Institute. (2018). *Genetic vs. Genomic Fact Sheet*. National Human Genome Research Institute.
- Nature Editorial. (2018). Epidemiology is a science of high importance. *Nature Communications*, 9(1), 1703. <https://doi.org/10.1038/s41467-018-04243-3>
- Noordraven, E. L., Schermer, M. H. N., Blanken, P., Mulder, C. L., & Wierdsma, A. I. (2017). Ethical acceptability of offering financial incentives for taking antipsychotic depot medication: Patients' and clinicians' perspectives after a 12-month randomized controlled trial. *BMC Psychiatry*, 17(1). <https://doi.org/10.1186/s12888-017-1485-x>
- Orellana, G., & Slachevsky, A. (2013). Executive functioning in schizophrenia. *Frontiers in Psychiatry*, 4, 35.
- Palmer, B. W., & Jeste, D. V. (2006). Relationship of individual cognitive abilities to specific components of decisional capacity among middle-aged and older patients with schizophrenia. *Schizophrenia Bulletin*, 32(1), 98–106. <https://doi.org/10.1093/schbul/sbj002>
- Palmer, B. W., Savla, G. N., Roesch, S. C., & Jeste, D. V. (2013). Changes in capacity to consent over time in patients involved in psychiatric research. *British Journal of Psychiatry*, 202(6), 454–458. <https://doi.org/10.1192/bjp.bp.112.121160>
- Patel, V. (2016). Universal health coverage for schizophrenia: a global mental health priority. *Schizophrenia Bulletin*, 42(4), 885–890.
- Read, J., Perry, B. D., Moskowitz, A., & Connolly, J. (2001). The contribution of early traumatic events to schizophrenia in some patients: a traumagenic neurodevelopmental model. *Psychiatry*, 64(4), 319–345. <https://doi.org/doi.org/10.1521/psyc.64.4.319.18602>
- Rittmannsberger, H. (2012). [The diagnosis “schizophrenia”: past, present and future]. *Psychiatr Danub*, 24(4), 408–414. <https://www.ncbi.nlm.nih.gov/pubmed/23132194>
- Roberts, L. W. (2002). Ethics and mental illness research. *Psychiatric Clinics*, 25(3), A525–A545. [https://doi.org/10.1016/S0193-953X\(01\)00014-4](https://doi.org/10.1016/S0193-953X(01)00014-4)
- Roberts, L. W., Green Hammond, K. A., Warner, T. D., & Lewis, R. (2004). Influence of ethical safeguards on research participation: Comparison of perspectives of

- people with schizophrenia and psychiatrists. *Am J Psychiatry*, *161*, 2309–2311.
<https://doi.org/10.1176/appi.ajp.161.12.2309>
- Roberts, L. W., Hammond, K. G., & Hoop, J. (2006). An inverse relationship between perceived harm and participation willingness in schizophrenia research protocols. *American Journal of Psychiatry*, *163*(11), 2002–2004.
<https://doi.org/10.1176/ajp.2006.163.11.2002>
- Roberts, L. W., & Kim, J. P. (2014). Giving voice to study volunteers: Comparing views of mentally ill, physically ill, and healthy protocol participants on ethical aspects of clinical research. *Journal of Psychiatric Research*, *56*(1), 90–97.
<https://doi.org/10.1016/j.jpsychires.2014.05.007>
- Roberts, L. W., Warner, T. D., Anderson, C. T., Smithpeter, M. V., & Rogers, M. K. (2004). Schizophrenia research participants' responses to protocol safeguards: Recruitment, consent, and debriefing. *Schizophrenia Research*, *67*(2–3), 283–291. [https://doi.org/10.1016/S0920-9964\(03\)00101-4](https://doi.org/10.1016/S0920-9964(03)00101-4)
- Roberts, L. W., Warner, T. D., & Brody, J. L. (2000). Perspectives of patients with schizophrenia and psychiatrists regarding ethically important aspects of research participation. *Am J Psychiatry*, *157*(1), 67–74.
<https://doi.org/https://doi.org/10.1176/ajp.157.1.67>
- Roberts, L. W., Warner, T. D., Brody, J. L., Nguyen, K., & Roberts, B. B. (2003). What is ethically important in clinical research? A preliminary study of attitudes of 73 psychiatric faculty and residents. *Schizophrenia Bulletin*, *29*(3), 607–613.
<https://doi.org/10.1093/oxfordjournals.schbul.a007032>
- Roberts, L. W., Warner, T. D., Green Hammond, K. A., & Geppert, C. M. A. (2006). Perspectives on medical research involving men in schizophrenia and HIV-related protocols. *Schizophrenia Bulletin*, *32*(2), 360–365.
<https://doi.org/10.1093/schbul/sbj015>
- Roberts, L. W., Warner, T. D., Hammond, K. G., & Hoop, J. G. (2006). Views of people with schizophrenia regarding aspects of research: Study size and funding sources. *Schizophrenia Bulletin*, *32*(1), 107–115.
<https://doi.org/10.1093/schbul/sbj022>
- Roberts, L. W., Warner, T. D., Nguyen, K. P., Geppert, C. M. A., Rogers, M. K., & Roberts, B. B. (2003). Schizophrenia patients' and psychiatrists' perspectives on ethical aspects of symptom re-emergence during psychopharmacological research participation. *Psychopharmacology*, *171*(1), 58–67.
<https://doi.org/10.1007/s00213-002-1160-9>

- Schmitt, A., Falkai, P., & Papiol, S. (2022). Neurodevelopmental disturbances in schizophrenia: evidence from genetic and environmental factors. *J Neural Transm (Vienna)*, 1–11. <https://doi.org/10.1007/s00702-022-02567-5>
- Seidman, L. J., & Mirsky, A. F. (2017). Evolving notions of schizophrenia as a developmental neurocognitive disorder. *Journal of the International Neuropsychological Society*, 23(9–10), 881–892. <https://doi.org/10.1017/S1355617717001114>
- Shore, D. (2006). *Ethical issues in schizophrenia research: a commentary on some current concerns*.
- Simpson, E. H., Kellendonk, C., & Kandel, E. (2010). A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. *Neuron*, 65(5), 585–596. <https://doi.org/10.1016/j.neuron.2010.02.014>
- Sims, J. M. (2010). A brief review of the Belmont report. *Dimensions of Critical Care Nursing*, 29(4), 173–174. <https://doi.org/10.1097/DCC.0b013e3181de9ec5>
- Streiner, D. L. (2007). Alternatives to placebo-controlled trials. *Canadian Journal of Neurological Sciences*, 34(S1), S37–S41. <https://doi.org/10.1017/s0317167100005540>
- Sugawara, N., Ishioka, M., Tsuchimine, S., Tsuruga, K., Sato, Y., Furukori, H., Kudo, S., Tomita, T., Nakagami, T., & Yasui-Furukori, N. (2015). Attitudes toward placebo-controlled clinical trials of patients with schizophrenia in Japan. *PLoS ONE*, 10(11), 1–8. <https://doi.org/10.1371/journal.pone.0143356>
- Tandon, R., Gaebel, W., Barch, D. M., Bustillo, J., Gur, R. E., Heckers, S., Malaspina, D., Owen, M. J., Schultz, S., Tsuang, M., van Os, J., & Carpenter, W. (2013). Definition and description of schizophrenia in the DSM-5. *Schizophr Res*, 150(1), 3–10. <https://doi.org/10.1016/j.schres.2013.05.028>
- Trémeau, F. (2006). A review of emotion deficits in schizophrenia. *Dialogues Clin Neurosci*, 8(1), 59–70. <https://doi.org/10.31887/DCNS.2006.8.1/ftremeau>
- Van De Laar, N., Henter, I., Bartko, J. J., & Wyatt, R. J. (2001). Adverse events during a placebo phase for inpatients with chronic schizophrenia. *Biological Psychiatry*, 50(7), 487–492. [https://doi.org/10.1016/s0006-3223\(01\)01225-2](https://doi.org/10.1016/s0006-3223(01)01225-2)
- Varkey, B. (2020). Principles of clinical ethics and their application to practice. *Med Princ Pract*, 30(1), 17–28. <https://doi.org/10.1159/000509119>

- Velligan, D. I., & Rao, S. (2023). The epidemiology and global burden of schizophrenia. *The Journal of Clinical Psychiatry*, 84(1), 45094. <https://doi.org/10.4088/JCP.MS21078COM5>
- Wang, L., McLeod, H. L., & Weinshilboum, R. M. (2011). Genomics and drug response. *New England Journal of Medicine*, 364(12), 1144–1153. <https://doi.org/10.1056/NEJMra1010600>
- Warner, T. D., Roberts, L. W., & Nguyen, K. (2003). Do psychiatrists understand research-related experiences, attitudes, and motivations of schizophrenia study participants? *Comprehensive Psychiatry*, 44(3), 227–233. <https://doi.org/10.1053/comp.2003.50022>
- Weisleder, P. (2021). Leo Alexander's Blueprint of the Nuremberg Code. *Pediatr Neurol*, 126, 120–124. <https://doi.org/10.1016/j.pediatrneurol.2021.10.015>
- Weiss Roberts, L., Warner, T. D., Brody, J. L., Roberts, B., Lauriello, J., & Lyketsos, C. (2002). Patient and psychiatrist ratings of hypothetical schizophrenia research protocols: Assessment of harm potential and factors influencing participation decisions. *Am J Psychiatry*, 159(4), 573–584. <https://doi.org/10.1176/appi.ajp.159.4.573>
- Wilson, S. T., & Stanley, B. (2006). Ethical concerns in schizophrenia research: Looking back and moving forward. *Schizophrenia Bulletin*, 32(1), 30–36. <https://doi.org/10.1093/schbul/sbj023>
- World Health Organization. (2022). *Schizophrenia*. World Health Organization.
- World Medical Association. (2013). World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA*, 310(20), 2191–2194. <https://doi.org/10.1001/jama.2013.281053>
- Wyatt, R. J., Henter, I. D., & Bartko, J. J. (1999). The Long-Term Effects of Placebo in Patients with Chronic Schizophrenia. *Biological Psychiatry*, 46(8), 1092–1105. [https://doi.org/10.1016/S0006-3223\(99\)00227-9](https://doi.org/10.1016/S0006-3223(99)00227-9)
- Zabor, E. C., Kaizer, A. M., & Hobbs, B. P. (2020). Randomized Controlled Trials. *Chest*, 158(1S), S79–S87. <https://doi.org/10.1016/j.chest.2020.03.013>
- Zipursky, R. B. (1999). Ethical issues in schizophrenia research. *Current Psychiatry Reports*, 1(1), 13–19. <https://doi.org/10.1007/s11920-999-0005-1>